Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
15.5.2019 19:53:00 EEST | Business Wire | Press release
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Interviews: “We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68 Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalized cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics. Scintomics considers the joint venture partnership with 1717 LSV as another important milestone towards a strong positioning as radiopharmaceutical development specialist.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of targeted precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005776/en/
Contact information
For Scintomics
Saskia Kropf
General Manager
tel.
+49 8141 150 550
s.kropf@scintomics.com
www.scintomics.com
For
1717 LSV
Dr. Jens Kaufmann
General Manager
tel. +49
30 941084-422
jens.kaufmann@1717LSV.com
www.1717LSV.com
For
PentixaPharm
Dr. Hakim Bouterfa
CEO
tel. +49 172
6290822 or +49 931 304998310
hakim.bouterfa@1717LSV.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Radial Selects Riskified to Power Payment Fraud and Refund/Return Protection for Merchant Client Portfolio9.3.2026 16:00:00 EET | Press release
Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced a strategic partnership with Radial, a leading 3PL set to become Paxon later this year. Radial will integrate with Riskified’s AI-powered platform to help its merchants approve more legitimate orders and reduce losses from payment fraud, including many merchants that use Shopify as their ecommerce platform. Radial supports many of the world’s most recognized retail brands with a global ecommerce fulfillment network of more than 20 centers across North America, helping merchants deliver orders quickly and cost effectively. By bringing Riskified’s AI-powered fraud decisioning into its commerce ecosystem, Radial gives merchants the surgical ability to calibrate the checkout experience according to risk—without slowing fulfillment. This also supports brands seeking to expand into new markets. Riskified empowers Radial's customers with accurate, real-time fraud decisions at checkout, approving or decl
Andersen to Announce Fourth-Quarter and Full-Year 2025 Financial Results9.3.2026 16:00:00 EET | Press release
Andersen Group Inc. (NYSE: ANDG) (“Andersen”), a leading provider of independent tax, valuation and financial advisory services to individuals and family offices, businesses and funds in the United States, will announce its financial results for the full year and fourth quarter 2025 after the market closes on Tuesday, March 17, 2026. Andersen CEO and Chairman, Mark L. Vorsatz, and Andersen Chief Financial Officer, Neal Livingston, will host a conference call to discuss Andersen’s financial results on Tuesday, March 17, 2026 at 5PM ET. Participants can join the webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3Hvslre. The webcast replay link will be archived on Andersen’s Investor Relations website at investor.andersen.com within a few hours of the event and will remain on the website for six months. About Andersen Andersen is a leading provider of independent tax, valuation and financial advisory services to individuals, family offices, businesses and alternat
Safe Software Announces the Peak of Data and AI 2027, a Premier Global Conference, in London, UK9.3.2026 15:00:00 EET | Press release
Safe Software (Safe) officially announced today the return of its global user conference, the Peak of Data and AI, taking place March 9–11, 2027, at the QEII Centre in London, UK. A Partner Summit will kick off the event on March 8, 2027, bringing together Safe’s global partner community ahead of the main conference. Hosted every two years, the Peak of Data and AI has evolved from Safe Software’s long-running user conference into a premier global event for data and AI professionals. The conference alternates between North America and international locations, with previous events held in Bonn, Germany (2023) and Seattle, Washington (2025). “At the Peak of Data and AI, we bring together the people who are shaping how organizations use data to drive real-world outcomes,” said Don Murray, CEO of Safe Software. “With London as our host city in 2027, we’re excited to connect with the global community to learn, listen, and share what’s next for data and AI.” The three-day conference will feat
Boomi Activates Data for the Enterprise9.3.2026 15:00:00 EET | Press release
Boomi™, the data activation company, today announced new capabilities within the Boomi Enterprise Platform. Data activation brings data to life across systems and processes, delivering it with the right context and timing to power everything from AI to BI. The Boomi Enterprise Platform, the foundation that puts data in motion, now adds new semantic context to help AI agents operate on grounded business realities, expands governed SAP data movement with change data capture, enhances transparency and oversight across agentic workflows, and introduces a dedicated European platform instance for localized data control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309682526/en/ Boomi Activates Data for the Enterprise “Last year, Boomi helped enterprises move from experimentation to execution. What we’re seeing now is clear: AI only delivers value when data is properly activated, trusted and governed first,” said Steve Lucas,
Thredd Accelerates in 2026 with its Global Platform and Delivering Enterprise-Scale Outcomes9.3.2026 15:00:00 EET | Press release
Thredd, the AI-first issuer processing platform, today announced a major acceleration phase for 2026, marked by the appointment of Marilyn McDonald as Chief Technology Officer and the promotion of Ryan Dew to Chief Product Officer. Thredd has never been in a stronger position. A fully cloud-native version of its global platform is live in the United States, with end-to-end credit capabilities launching in the coming months alongside a state-of-the-art debit platform and modern unified ledger. Marilyn McDonald joins as CTO to lead the next phase of enterprise-scale execution. She succeeds Edwin Poot, who helped lead the modernisation of Thredd’s architecture and technology stack, laying the foundation for cloud-native and agentic growth. Marilyn brings global transformation experience from senior roles at Citigroup, Mastercard, Expedia Group and StubHub. Her focus is on strengthening operational readiness, bank-grade delivery, enterprise execution and continuous resilience as Thredd sca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom